Superseded · version 2: TB-500^↗↗

Related names recorded in this version: N-terminal acetylated 17-23 fragment of thymosin beta-4^↗↗

A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.^↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.

Update · July 29, 2026

We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination. ²³

What this version reported

FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.^↗↗↗

Organizations named in cited records:

U.S. Food and Drug Administration^↗↗↗

Sources for this version

1
TB-500 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
2
FDA briefing document for TB-500 ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
3
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026